MedTrace Logo

Atrasentan in Patients With Proteinuric Glomerular Diseases

NCT04573920 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2025-08-11

No results posted yet for this study

Summary

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

Conditions

  • IgA Nephropathy
  • Focal Segmental Glomerulosclerosis
  • Alport Syndrome
  • Diabetic Kidney Disease
  • Diabetic Nephropathy Type 2
  • Immunoglobulin A Nephropathy

Interventions

DRUG

Atrasentan

Film-coated tablet

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-15
Primary Completion
2024-07-02
Completion
2026-10-27
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Italy
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04573920 on ClinicalTrials.gov